… Nevertheless, our observational study provides Class IV evidence 18 for the superiority of
natalizumab over fingolimod to prevent relapse at 1 year. Regarding the absence of RCTs and …

… This French observational study including 740 patients with a … for FNG in terms of
effectiveness and tolerance. A sharp … Two Swedish studies based on multicentric cohorts [11, 12] …

… comparing the efficacy of NTZ and FTY. Among those studies, six were mono- or multicentric
retrospective studies and … available in France. Including those drugs in future head-to-head …

… Natalizumab and fingolimod are used as high-efficacy treatments in relapsing–remitting
multiple sclerosis. Several observational studies comparing … Registry and French OFSEP registry…

… Both natalizumab and fingolimod are highly effective in the … , some observational studies
have compared their efficacy … RRMS patients who started natalizumab or fingolimod in three MS …

… We observed a comparable efficacy on ARR reduction and on … Eventually, a large-scale study
conducted in 27 French MS … the study, likewise previously published observational studies, …

… The primary objective was to assess the efficacy and the safety of Fg in patients with MS in
daily practice. We focused on (i) the comparison between ARR the year before Fg onset and …

… We evaluated the comparative efficacy of FGD vs. NTZ using a … a 9-year multicenter,
cross-sectional, clinical-MRI study of 241 … and observational study data suggest that Natalizumab …

… -head trial assessing the comparative efficacy of these two agents … be confirmed in a French
multicenter cohort study including 629 … observational studies, we found that natalizumab and …

… patients with RRMS treated with fingolimod from 2010 to 2019 in 4 French MS referral centers.
… natalizumab. Our population is more comparable to the real-world observational studies …